These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 4252802)

  • 21. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin.
    Reed GL; Matsueda GR; Haber E
    Thromb Haemost; 1992 Sep; 68(3):315-20. PubMed ID: 1279832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrin-fibrinogen degradation products in allergic disorders.
    Palma-Carlos AG; de Sá A; Joana-Geraldes M; Ducla-Soares J; Migueis-Clode MH
    Allergol Immunopathol (Madr); 1974; 2(6):419-22. PubMed ID: 4282697
    [No Abstract]   [Full Text] [Related]  

  • 23. Effector mechanisms and products of the physiological fibrinolytic systems.
    Edgington TS; Plow EF
    Prog Clin Biol Res; 1976; 5():85-120. PubMed ID: 61595
    [No Abstract]   [Full Text] [Related]  

  • 24. [Analysis of lytic effect on fibrin of immobilized heparin in complex with plasma proteins].
    Platé NA; Valuev LI; Gumirova FKh; Maklakova IA
    Vopr Med Khim; 1982; 28(5):19-23. PubMed ID: 6217639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Action of anti-plasmin in activation of the fibrinolysis system and its clinical management].
    Tabara C; Hitano E; Mizuno Y; Kazama M; Abe H
    Rinsho Byori; 1974 Oct; 22(10 Suppl):105. PubMed ID: 4281036
    [No Abstract]   [Full Text] [Related]  

  • 26. Nature and biological activities of degradation products of fibrinogen and fibrin.
    Kwaan HC; Barlow GH
    Annu Rev Med; 1973; 24():335-44. PubMed ID: 4575863
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of ethanol and protamine tests in demonstration of soluble fibrin and early products of fibrin degradation.
    Konttinen YP; Kemppainen L; Turunen O
    Thromb Diath Haemorrh; 1972 Dec; 28(3):342-50. PubMed ID: 4675265
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical significance of fibrinogen/fibrin degradation products (F/F DP)].
    Alakhverdian R
    Vutr Boles; 1979; 18(3):160-7. PubMed ID: 89851
    [No Abstract]   [Full Text] [Related]  

  • 29. [FDP in newborn period. Especially the FDP and fibrin monomers in respiratory distress syndrome of premature infants].
    Yamada K; Shirahata A; Meguro T; Nakazawa S
    Nihon Ketsueki Gakkai Zasshi; 1972 Oct; 35(5):646-50. PubMed ID: 4677381
    [No Abstract]   [Full Text] [Related]  

  • 30. Plasmin lysis of fibrinogen and fibrin and the antigenic properties of their degradation products.
    Ekert H; Muntz RH
    Br J Haematol; 1972 Jan; 22(1):103-10. PubMed ID: 4258329
    [No Abstract]   [Full Text] [Related]  

  • 31. Human fibrinogen.
    Shafer JA; Higgins DL
    Crit Rev Clin Lab Sci; 1988; 26(1):1-41. PubMed ID: 3286116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the thrombin clotting time. II. The influence of fibrin degradation products.
    Arnesen H
    Scand J Haematol; 1973; 10(4):291-7. PubMed ID: 4764611
    [No Abstract]   [Full Text] [Related]  

  • 33. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinogen-fibrin system regulators from bloodsuckers.
    Zavalova LL; Basanova AV; Baskova IP
    Biochemistry (Mosc); 2002 Jan; 67(1):135-42. PubMed ID: 11841348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH.
    Plow EF; Edgington TS
    J Clin Invest; 1975 Jul; 56(1):30-8. PubMed ID: 237938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolytic degradation products from fibrinogen and fibrin with special respect to non-covalently associated complexes. Influence of fibrin crosslinking. Lysability and other properties.
    Feddersen C
    Scand J Clin Lab Invest Suppl; 1983; 166():1-60. PubMed ID: 6226084
    [No Abstract]   [Full Text] [Related]  

  • 37. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
    Sakata Y; Aoki N
    J Clin Invest; 1980 Feb; 65(2):290-7. PubMed ID: 6444305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
    Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A microtiter plate assay for factor XIII A-chain-fibrin interactions.
    Achyuthan KE; Santiago MA; Greenberg CS
    Anal Biochem; 1994 May; 219(1):43-8. PubMed ID: 8059954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of intravascular and extravascular coagulation on serum fibrin degradation products in rats.
    Vanstone JC; Khoury NY
    Thromb Diath Haemorrh; 1971; 25(1):142-6. PubMed ID: 4996073
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.